

**Table S1** Baseline demographics and clinical characteristics: COAST-V and COAST-W (Extended Treatment Period Population)

	COAST-V (bDMARD-naïve)				COAST-W (TNFi-experienced)		
	PBO/ IXE (N=86)	ADA/ IXE (N=86)	IXE Q4W/ IXE Q4W (N=78)	IXE Q2W/ IXE Q2W (N=79)	PBO/ IXE (N=93)	IXE Q4W/ IXE Q4W (N=98)	IXE Q2W/ IXE Q2W (N=90)
Age, mean (SD), years	42.7 (12.0)	41.5 (11.6)	40.8 (11.8)	41.2 (11.4)	47.1 (12.7)	47.1 (13.3)	44.5 (10.5)
Male sex	71 (82.6)	70 (81.4)	65 (83.3)	61 (77.2)	77 (82.8)	81 (82.7)	68 (75.6)
Race							
White	52 (60.5)	56 (65.1)	51 (65.4)	50 (63.3)	77 (82.8)	78 (80.4)	72 (80.0)
Asian	28 (32.6)	26 (30.2)	23 (29.5)	23 (29.1)	11 (11.8)	12 (12.4)	11 (12.2)
Other	6 (7.0)	4 (4.7)	4 (5.1)	6 (7.6)	5 (5.4)	7 (7.2)	7 (7.8)
Weight, mean (SD)	79.9 (17.1)	78.6 (17.3)	77.8 (14.9)	76.8 (13.9)	85.0 (17.5)	86.2 (20.1)	79.0 (17.1)
Duration of symptoms, mean (SD), years	16.6 (10.1)	15.7 (9.4)	15.8 (11.0)	15.7 (10.9)	20.2 (11.8)	18.2 (11.1)	16.6 (9.3)
Time since axial SpA diagnosis, mean (SD), years	6.8 (7.6)	7.6 (7.5)	8.3 (9.5)	8.2 (9.1)	13.1 (10.7)	9.7 (8.0)	11.6 (8.4)
HLA-B27 positive	76 (89.4)	78 (90.7)	72 (92.3)	73 (92.4)	76 (81.7)	81 (82.7)	73 (81.1)
CRP concentration (mg/L), mean (SD)	16.0 (21.0)	12.8 (17.9)	12.5 (13.5)	13.0 (15.2)	17.2 (23.3)	19.5 (34.1)	17.1 (20.4)
CRP >5 mg/L	60 (69.8)	51 (59.3)	52 (66.7)	51 (64.6)	60 (64.5)	61 (62.2)	65 (72.2)
ASDAS, mean (SD)	3.9 (0.7)	3.7 (0.9)	3.7 (0.7)	3.8 (0.8)	4.1 (0.8)	4.2 (0.8)	4.1 (0.8)
BASDAI, mean (SD)	6.8 (1.2)	6.6 (1.5)	6.8 (1.3)	6.7 (1.6)	7.3 (1.3)	7.4 (1.3)	7.4 (1.2)
BASFI, mean (SD)	6.4 (1.9)	6.1 (2.0)	6.1 (1.8)	6.3 (2.1)	7.0 (1.7)	7.2 (1.8)	7.4 (1.4)
BASMI linear, mean (SD)	4.5 (1.5)	4.2 (1.6)	3.9 (1.5)	4.0 (1.4)	4.9 (1.5)	4.6 (1.5)	4.7 (1.5)
Medication use							
Methotrexate	8 (9.3)	8 (9.3)	9 (11.5)	3 (3.8)	17 (18.3)	11 (11.2)	9 (10.0)
Sulfasalazine	23 (26.7)	24 (27.9)	24 (30.8)	24 (30.4)	13 (14.0)	16 (16.3)	16 (17.8)

Oral corticosteroid	6 (7.0)	9 (10.5)	12 (15.4)	5 (6.3)	13 (14.0)	9 (9.2)	11 (12.2)
NSAIDs	78 (90.7)	80 (93.0)	71 (91.0)	76 (96.2)	75 (80.6)	75 (76.5)	64 (71.1)
1 prior TNFi	NA	NA	NA	NA	58 (62.4)	62 (63.3)	63 (70.0)
2 prior TNFi	NA	NA	NA	NA	35 (37.6)	36 (36.7)	27 (30.0)

Data are n (%) unless otherwise indicated.

ADA, adalimumab; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; bDMARD, biological disease-modifying antirheumatic drug; CRP, C-reactive protein; HLA, human leucocyte antigen; IXE Q4W, ixekizumab 80 mg every 4 weeks; IXE Q2W, ixekizumab 80 mg every 2 weeks; MRI, magnetic resonance imaging; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug; PBO, placebo; SD, standard deviation; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.